News

BioM's articles and press releases about the Bavarian biotechnology sector


High expectations at MorphoSys

Two stud­ies un­der­line the im­port­ance of tar­get mo­lecule of the drug can­did­ate against rheum­at­oid arth­rit­is

Impressive pipeline for personalized medicine

Roche presents its de­vel­op­ment pipeline and com­mits it­self to Per­son­al­ized Medi­cine

MorphoSys attracts investors from the US

After Mark Lampert now also Mor­gan Stan­ley in­vests in Mu­nich's bi­otech local hero

Investors trust WILEX

Com­bined cap­it­al in­crease suc­cess­fully com­pleted totalling EUR 23.9 mil­lion

Registration is opened

Pre­lim­in­ary pro­gramme of the 2nd Mu­nich Bio­mark­er Con­fer­ence, Novem­ber 22nd-23rd

Japanese health care and pharma industry

Op­por­tun­it­ies for Ger­man life sci­ence SMEs

MorphoSys Antibody Reaches Major Milestone in Collaboration with Roche

Alzheimer Antibody Gantener­u­mab Clin­ic­al Trial Ex­pan­ded to Pivotal Phase 2/3 Study

Infoveranstaltung: Förderinstrumente für KMU

EU-Forschungs­för­der­ung in den Lebenswis­senschaften

Bavarian Biotechnology is doing very well

Just pub­lished: the Year-2011-sur­vey of the Bav­ari­an Bi­o­tech­nolgy In­dustry re­veals good pro­gress in em­ploy­ment, pipeline and…

m⁴ eAcademy visits m⁴ Seminar

Re­cord­ing of the talks by Prof. Friess, MRI and Dr. Simon, Agen­dia